Clinical Trials
40 trialsCINC424A2X01B Rollover Protocol
Novartis
Study to Assess Adverse Events and Change in Disease Activity of Oral Venetoclax in Combination With Subcutaneous (SC) or Intravenous (IV) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Standard Induction Therapy in India
AbbVie
AML
Fujian Medical University Union Hospital
Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies
Rigel Pharmaceuticals
REMAIN1
Virginia Commonwealth University
Ciprofloxacin vs Ceftazidime for Empirical Treatment of High-Risk Neutropenic Fever in Children With Hematologic Malignancies
Gadjah Mada University
Study to Assess Adverse Events and Change in Disease State of Oral Venetoclax in Combination With Subcutaneous (SC) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy in China
AbbVie
CLAG+VEN vs CLAG in the Treatment of Relapsed/Refractory AML
Nanfang Hospital, Southern Medical University
Fludarabine and Cytarabine Versus High-dose Cytarabine for CBF-AML
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Antimicrobial Revision in Persistent Febrile Neutropenia
Wake Forest University Health Sciences
RIC Allo-HSCT vs. Venetoclax-Based Consolidation in Elderly AML Patients After First CR
Zhejiang University
A Rollover Study to Provide Continued Treatment With Eltrombopag
Novartis
Patients Receiving Induction With Liposomal Daunorubicin and Cytarabine (CPX-351) for Acute Myeloid Leukemia
Medical College of Wisconsin
Azacytidine + HAG Regimen vs. Azacytidine for Elderly Patients With Newly Diagnosed Myeloid Malignancy
Shenzhen Second People's Hospital
Ikervis
Singapore Eye Research Institute
King's Invasive Aspergillosis Study II
King's College Hospital NHS Trust
Bone Marrow Transplantation in Treating Patients With Hematologic Cancer
University of Maryland, Baltimore
G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome
Memorial Sloan Kettering Cancer Center
LAMVIRE
Centre Hospitalier Universitaire, Amiens
Maintenance Therapy With Ceplene® (Histamine) and IL-2 on Immune Response and MRD in Acute Myeloid Leukemia
Cytovia, Inc.
Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking
University of Kansas Medical Center
Early Tapering of Immunosuppressive Agents to Immunomodulation to Improve Survival of AML Patients
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Oral Posaconazole in High Risk Patients With Gastrointestinal Dysfunction (Study P05115)
Merck Sharp & Dohme LLC
Decitabine Versus Conventional Chemotherapy for Maintenance Therapy of Acute Myeloid Leukemia With t(8;21)
The First Hospital of Jilin University
Interferon for the Intervention of Molecular Relapse in t (8; 21) AML After Allo-HSCT
Peking University People's Hospital
Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking
Fox Chase Cancer Center
Idarubicin at Different Dosages as Induction Therapy for Newly Diagnosed Acute Myeloid Leukaemia
Guangdong Provincial People's Hospital
3 Anthracyclines, 2 Types of Consolidation With Different ARA-C Doses and Maintenance in Adult Acute Myeloid Leukemia
National Research Center for Hematology, Russia
AML1-ETO Acute Myeloid Leukemia With Fludarabine and Cytarabine Chemotherapy
Changhai Hospital
LAM07: Study to Analyze the Efficacy of a Risk Adapted Treatment Strategy, Including Gemtuzumab Ozogamicin (GO) During Consolidation, for Patients With Acute Myeloid Leukemia (AML)
PETHEMA Foundation
DFMBHSCT
The First Affiliated Hospital of Soochow University
Therapy of Acute Myeloid Leukemia in Patients Over the Age of 60 : DA Versus Mitoxantrone With Intermittent AraC
Technische Universität Dresden
Treatment of the Acute Myeloblastic Leukaemia in Patients Over 65 Years
PETHEMA Foundation
AML2003 - Standard-Therapy vs Intensified Therapy for Adult Acute Myeloid Leukemia Patients <= 60 Years
Technische Universität Dresden
Study Evaluating the Effect of Corticosteroids on Mylotarg® Infusion-Related Adverse Events in Patients With Leukemia
Wyeth is now a wholly owned subsidiary of Pfizer
FLAG-IDA
PETHEMA Foundation
FLAT
PETHEMA Foundation
AML96 - Risk-Adapted and Randomized Postremission-Therapy for Adult Acute Myeloid Leukemia Patients
Technische Universität Dresden
Efficacy of G-CSF-Priming in Elderly AML Patients
Johann Wolfgang Goethe University Hospital